- Home
- MVST vs SCPH Comparison
MVST vs SCPH Comparison
Compare MVST & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVST
- SCPH
- Stock Information
- Founded
- MVST 2006
- SCPH 2013
- Country
- MVST United States
- SCPH United States
- Employees
- MVST N/A
- SCPH N/A
- Industry
- MVST Industrial Machinery/Components
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- MVST Miscellaneous
- SCPH Health Care
- Exchange
- MVST Nasdaq
- SCPH Nasdaq
- Market Cap
- MVST 182.8M
- SCPH 179.6M
- IPO Year
- MVST N/A
- SCPH 2017
- Fundamental
- Price
- MVST $1.99
- SCPH $3.51
- Analyst Decision
- MVST Buy
- SCPH Strong Buy
- Analyst Count
- MVST 3
- SCPH 2
- Target Price
- MVST $3.33
- SCPH $15.00
- AVG Volume (30 Days)
- MVST 20.2M
- SCPH 448.7K
- Earning Date
- MVST 11-12-2024
- SCPH 11-13-2024
- Dividend Yield
- MVST N/A
- SCPH N/A
- EPS Growth
- MVST N/A
- SCPH N/A
- EPS
- MVST N/A
- SCPH N/A
- Revenue
- MVST $370,989,000.00
- SCPH $30,278,000.00
- Revenue This Year
- MVST $19.19
- SCPH $172.64
- Revenue Next Year
- MVST $29.35
- SCPH $131.43
- P/E Ratio
- MVST N/A
- SCPH N/A
- Revenue Growth
- MVST 39.03
- SCPH 303.87
- 52 Week Low
- MVST $0.15
- SCPH $3.08
- 52 Week High
- MVST $2.87
- SCPH $6.54
- Technical
- Relative Strength Index (RSI)
- MVST 54.10
- SCPH 50.42
- Support Level
- MVST $1.82
- SCPH $3.27
- Resistance Level
- MVST $2.87
- SCPH $3.58
- Average True Range (ATR)
- MVST 0.46
- SCPH 0.18
- MACD
- MVST -0.05
- SCPH 0.02
- Stochastic Oscillator
- MVST 40.14
- SCPH 52.94
About MVST Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extend from core battery chemistry to battery packs.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.